SPEAR qPCR cross-platform compatibility for an immunoassay platform with unparalleled robustness

Presented at AAIC 2025

Background:
Neurodegenerative diseases such as Alzheimer’s disease (AD) require highly sensitive and specific diagnostic tools for early detection and monitoring. Immunoassay-based detection of disease-associated biomarkers in biofluids shows promise but faces challenges in sensitivity, reproducibility, and scalability. Our study presents a semi-automated immunoassay workflow powered by SPEAR (Successive Proximity Extension Amplification Reaction) technology to enhance detection capabilities and enable high-throughput biomarker analysis. Robustness was demonstrated through consistent results across different qPCR instruments, highlighting the method’s adaptability in diverse laboratory settings.

Download the poster to learn more.